Proteros´ Discovery Pipeline business model offers research collaborations with exclusively partnered projects. Such drug discovery collaborations with pharmaceutical partners open new gateways to innovative and technically challenging epigenetic targets and embark on promising new approaches in cancer research.
We are seeking for partners to collaboratively access epigenetic targets using Proteros´ best-in-class drug discovery platform NEATTM for the investigation of technically challenging epigenetic oncology drug targets, including those identified by Proteros and those of interest to the partners.
Proteros offers unique and flexible partnering opportunities along the entire discovery value chain from novel target to in vivo active lead series. Our current proprietary pipeline includes projects ready for partnering in the early stages of discovery, providing a flexible partnering window for new partners.
In our pipeline, we focus on technically demanding epigenetic targets that address novel, unexplored and disruptive disease mechanisms in oncology with specific hypotheses for differentiation against standard of care, where our technology platform is pivotal to the project´s success.
We leverage Proteros’ core competencies and engage with our partners from academia, biotech and pharma companies, as well as with key opinion leaders from world-wide leading clinical research centers.
Dr. Torsten Neuefeind
Chief Executive Officer and Co-founder